Chimeric Antigen Receptor T Cell Therapy for Hepatocellular Carcinoma: Where Do We Stand?
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25052631 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Ioanna Aggeletopoulou und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Department of Internal Medicine, University Hospital of Patras, 26504 Patras, Greece. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Receptors, Chimeric Antigen, Liver Neoplasms. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 166 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Hepatocellular carcinoma (HCC) remains a global health challenge that urgently calls for innovative therapeutic strategies. Chimeric antigen receptor T cell (CAR T) therapy has emerged as a promising avenue for HCC treatment. However, the therapeutic efficacy of CAR T immunotherapy in HCC patients is significantly compromised by some major issues including the immunosuppressive environment within the tumor, antigen heterogeneity, CAR T cell exhaustion, and the advanced risk for on-target/off-tumor toxicity. To overcome these challenges, many ongoing preclinical and clinical trials are underway focusing on the identification of optimal target antigens and the decryption of the immunosuppressive milieu of HCC. Moreover, limited tumor infiltration constitutes a significant obstacle of CAR T cell therapy that should be addressed. The continuous effort to design molecular targets for CAR cells highlights the importance for a more practical approach for CAR-modified cell manufacturing. This review critically examines the current landscape of CAR T cell therapy for HCC, shedding light on the changes in innate and adaptive immune responses in the context of HCC, identifying potential CAR T cell targets, and exploring approaches to overcome inherent challenges. Ongoing advancements in scientific research and convergence of diverse treatment modalities offer the potential to greatly enhance HCC patients’ care in the future.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Gastroenterology, Department of Internal Medicine, University Hospital of Patras, 26504 Patras, Greece.
- Department of Gastroenterology, General Hospital of Patras, 26332 Patras, Greece.
ORCID-Profile: Ioanna Aggeletopoulou, Christos Triantos
Zitieren
APA
Aggeletopoulou, I., Kalafateli, M., & Triantos, C. (2024). Chimeric Antigen Receptor T Cell Therapy for Hepatocellular Carcinoma: Where Do We Stand?. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25052631
Vancouver
Aggeletopoulou I, Kalafateli M, Triantos C. Chimeric Antigen Receptor T Cell Therapy for Hepatocellular Carcinoma: Where Do We Stand?. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25052631
BibTeX
@article{Aggeletopoulou2024,
author = {Aggeletopoulou, Ioanna and Kalafateli, Maria and Triantos, Christos},
title = {Chimeric Antigen Receptor T Cell Therapy for Hepatocellular Carcinoma: Where Do We Stand?},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25052631}
}
EUVIMED